News >

Recurrent Ovarian Cancer Paradigm Continues to Evolve

Caroline Seymour
Published: Wednesday, Aug 21, 2019

Madeleine B. Courtney Brooks, MD, MPH, a gynecologic oncologist at the University of Pittsburgh Medical Center

Madeleine B. Courtney Brooks, MD, MPH

Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.  
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication